



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

November 13, 2020

Michael Cain
Chief Executive Officer and Director
Inspyr Therapeutics, Inc.
2629 Townsgate Road #215
Westlake Village, CA 91361

Re: Inspyr Therapeutics, Inc.
Preliminary Information Statement on Schedule 14C
Filed October 16, 2020
File No. 000-55331

Dear Mr. Cain:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Raul Silvestre